Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

scientific article published on 01 October 2019

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/IJNP/PYZ039
P932PMC publication ID6822141
P698PubMed publication ID31290965

P50authorPierre U. BlierQ46045677
P2093author name stringMaurizio Fava
Michael Liebowitz
David Hough
Pilar Lim
Rosanne Lane
Wayne C Drevets
Husseini Manji
Madhukar Trivedi
Arun Ravindran
Sheldon Preskorn
Raphael Gaillard
Maggie Fedgchin
Jaskaran B Singh
Ella J Daly
Rama Melkote
Dawn Vitagliano
Hans Van Den Ameele
P2860cites workMorbidity in Depressive DisordersQ47973002
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.Q52587655
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.Q64966336
Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)Q74233384
General multistage gatekeeping proceduresQ79643921
Mixtures of multiple testing procedures for gatekeeping applications in clinical trialsQ83902220
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled StudyQ92165468
Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New ClassQ92217233
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorderQ28291261
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportQ29615999
Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health QuestionnaireQ33777234
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled StudyQ34506620
A brief measure for assessing generalized anxiety disorder: the GAD-7.Q34529333
Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA).Q34733035
Diagnosis and definition of treatment-resistant depressionQ35111568
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015.Q35560309
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsQ37197216
Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressantsQ37246423
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.Q37281749
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?Q37439244
The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments.Q37709437
RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ).Q43273547
Assessing psychiatric impairment in primary care with the Sheehan Disability ScaleQ46084388
Physician Withdrawal Checklist (PWC-20).Q46484513
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: aQ47198959
Adaptive sample size calculations in group sequential trialsQ47213254
Modification of sample size in group sequential clinical trialsQ47213272
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical TrialQ47667772
P275copyright licenseCreative Commons Attribution-NonCommercial 4.0 InternationalQ34179348
P6216copyright statuscopyrightedQ50423863
P433issue10
P921main subjecttreatment-resistant depressionQ7836891
P304page(s)616-630
P577publication date2019-10-01
P1433published inThe International Journal of NeuropsychopharmacologyQ7742309
P1476titleEfficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
P478volume22

Reverse relations

cites work (P2860)
Q96811669A systematic review of ketamine for the treatment of depression among older adults
Q89842826Approval of esketamine for treatment-resistant depression
Q89842828Approval of esketamine for treatment-resistant depression - Authors' reply
Q98830300Benefit-Risk Assessment of Esketamine Nasal Spray versus Placebo in Treatment-Resistant Depression
Q93020534Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Q94450996Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
Q89626651Conformational flexibility within the small domain of human serine racemase
Q94451007Esketamine clinical trials: reply to Maju et al
Q92003437Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Q91077725Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
Q98386641Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
Q98158719Genome-wide association study and polygenic risk score analysis of esketamine treatment response
Q95642618Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers

Search more.